Biogen Idec Management Discusses Q2 2012 Results – Earnings Call Transcript – Seeking Alpha
BloombergBiogen Idec Management Discusses Q2 2012 Results – Earnings Call TranscriptSeeking AlphaMoving on to daclizumab. We completed enrollment in this side, the second registrational trial for daclizumab and relapsing-remitting MS with more than 180…
